Abhishek Singhal, associate director at Macquarie Capital Securities, says it is too early to come to a conclusion that all the FDA issues are behind Lupin. But he maintains that July 2015 inspection is all-clear is definitely a better situation for Lupin to be in rather than the entire 18 observations outstanding.
